Article

Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Cancer (Impact Factor: 4.9). 02/2012; 118(4):981-6. DOI: 10.1002/cncr.26375
Source: PubMed

ABSTRACT Refractory germ cell tumor (GCT) patients have a poor prognosis and limited treatment options. The identification of novel active agents may be impaired by use of response as the primary endpoint in phase 2 trials. Improved endpoints could enhance the development of new effective agents.
The characteristics and outcome of refractory GCT patients enrolled in 7 single-agent phase 2 trials conducted at Memorial Sloan-Kettering Cancer Center from 1990 to 2008 were reviewed. The study agents were suramin, all-transretinoic acid, topotecan, pyrazoloacridine, temozolomide, ixabepilone, and sunitinib. The major endpoints evaluated were response, progression-free survival (PFS), and overall survival (OS).
Ninety patients (87 male, 3 female) were treated. The primary tumor site was testis in 65 patients, mediastinum in 17 patients, retroperitoneum in 4 patients, and other in 4 patients. Eighty-six patients had nonseminoma, and 4 patients had pure seminoma. Best responses were 1 (1%) partial response (ixabepilone), 15 (17%) stable disease, and 74 (82%) progressive disease. Median PFS and OS were 1.0 month (95% confidence interval [CI], 0.8-1.3) and 4.7 months (95% CI, 3.5-6.4), respectively. Eighty-six of the 90 patients have died. The 12- and 16-week PFS rates were 9% (95% CI, 3-15%) and 6% (95% CI, 1%-11%), respectively.
Patients with refractory GCT progressed rapidly to these single agents. PFS and OS may be useful endpoints for designing phase 2 trials testing novel agents in this population. Twelve-week PFS (with comparison to the 9% benchmark rate reported herein) is the recommended endpoint for phase 2 trial design and median OS (using 4.7 months as the predicted median for the control arm) is suggested for phase 3 trials.

0 Followers
 · 
93 Views
 · 
0 Downloads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Tivantinib is a selective, small-molecule inhibitor of the MET receptor tyrosine kinase. Preclinical and phase 1 data suggested a possible role for MET in the pathophysiology of germ cell tumors (GCTs) and a potential clinical benefit from tivantinib in patients with these tumors. Methods Men (≥16 years) with relapsed or refractory, histologically confirmed, non-central nervous system GCTs received oral tivantinib 360 mg twice daily in 28-day cycles until progressive disease or unacceptable toxicity. The primary endpoint was objective response rate in the first 4 cycles, with study termination for <2 responses among the first 21 patients. Secondary endpoints included 12-week progression-free survival (PFS), overall survival (OS), and safety. Results Twenty-seven patients were enrolled in 9 months (median age, 32 years). Most patients had tumors with nonseminoma histology (n = 25), and primary tumor sites were testis (n = 24) and mediastinum (n = 3). Among 25 evaluable patients, no objective responses were observed; accrual was halted when the 21st patient became evaluable. Best response was stable disease (n = 5). Median PFS was 1 month, the 12-week PFS rate was 21 %, and median OS was 6 months. Grade 3 or 4 adverse events considered related to study drug included grade 3 pneumonia and grade 3 syncope (n = 1, each). Conclusions Tivantinib was well tolerated but did not demonstrate single-agent activity in patients with relapsed/refractory GCTs. Rapid accrual to this phase 2 trial was achieved in this rare patient population through multicenter collaboration.
    Investigational New Drugs 02/2013; 31(4). DOI:10.1007/s10637-013-9934-y · 2.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE:: CD30 is expressed by untreated embryonal carcinoma (ECA) thus lending support to a rationale for a targeted approach. However, authors reported a chemotherapy-induced switch-off of CD30 at immunohistochemistry that might affect the therapeutic potential in relapsing disease. We aimed at evaluating the persistence of CD30-expression and its prognostic meaning in post-chemotherapy residuals. MATERIALS AND METHODS:: Paraffin blocks of surgical samples yielding non-teratoma viable cells after = 1 cisplatin-based chemotherapy were retrieved and re-assessed by two pathologists blinded to study purpose. Multivariable analyses (MVA) for pre-specified factors were undertaken. RESULTS:: From August 1991 to August 2012, a total of 49 cases of pure ECA or mixed germ-cell tumor had full clinical data and suitable tissue for analyses. Thirty-five cases (71.4%; 95% CI: 56.7-83.4%) preserved CD30 positivity. Of them, 14 (40.0%) had residual disease after after multiple regimens (median 1, IQR 1-2). Five-year overall survival of CD30-positive and negative patients was 37.0% (22.1-61.8%) and 50.1% (27.9-90.0%), respectively (p=0.078) while it was 23.2% (8.6-62.5%) and 47.6% (18.8-100%, p=0.025) beyond first-line. At MVA, CD30-positivity was a significant prognostic factor for progression-free (HR: 2.32; 95% CI: 1.04-5.19) and overall survival (HR: 2.77; 95% CI: 1.05-7.29). CONCLUSIONS:: CD30 was retained even after an intensive pre-treatment load, thus confirming to be a reliable target for treatment. Its expression associated with a significant poorer prognosis in multi-relapsed/chemoresistant cases and it was an independent prognostic factor for survival.
    The Journal of urology 04/2013; 190(5). DOI:10.1016/j.juro.2013.04.057 · 3.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The transforming growth factor-β1 (TGF-β1)/Smad3 signaling pathway has a central role in pathogenesis of lung fibrosis. In the present study, we investigated if all-trans retinoic acid (ATRA) could attenuate fibrosis in bleomycin (BLM)-induced lung fibrosis in rats through regulating TGF-β1/Smad3 signaling. Beginning on day 14 after BLM administration, the ATRA I and II groups of rats received daily oral administration of ATRA for 14 days. All rats were killed on day 28. Lung tissue sections were prepared and subject to histological assessment, and expression levels of proteins involved in the TGF-β1 signaling cascade and epithelial-mesenchymal transition (EMT) were evaluated by transmission electron microscopy (TEM), quantitative real-time polymerase chain reaction (qRT-PCR), western blot procedure, and immunohistochemical or immunofluorescence staining. BLM significantly increased the alveolar septum infiltrates, inflammatory cell infiltrates, and collagen fibers. These BLM-induced changes were significantly ameliorated by ATRA treatment. In addition, BLM significantly increased levels of lung fibrosis markers α-SMA, hydroxyproline (Hyp), collagen I, Snail, and Twist, whereas significantly decreased E-cadherin expression. ATRA treatment largely reversed BLM-induced changes in these lung fibrosis markers. ATRA also blocked BLM-induced activation of the TGF-β1/Smad3 signaling pathway in lung tissues, including expression of TGF-β1, Smad3, p-Smad3, zinc-finger E-box-binding homeobox 1 and 2 (ZEB1 and ZEB2), and the high-mobility group AT-hook 2 (HMGA2). Our results suggest that ATRA may have potential therapeutic value for lung fibrosis treatment.Laboratory Investigation advance online publication, 16 September 2013; doi:10.1038/labinvest.2013.108.
    Laboratory Investigation 09/2013; 93(11). DOI:10.1038/labinvest.2013.108 · 3.83 Impact Factor
Show more

Preview (2 Sources)

Download
0 Downloads